Alstem

Executive Summary

Alstem is a privately held U.S. biotechnology company founded in 2008, specializing in contract research and development services for cell therapy and regenerative medicine. Headquartered in Richmond, California, the company offers a suite of expertise including induced pluripotent stem cell (iPSC) reprogramming, CRISPR gene editing, virus packaging, and stable cell line generation. By integrating advanced protein analysis technologies like HiBiT and NanoLuc, Alstem enables the creation of custom cellular models that accelerate research for academic, biotech, and pharmaceutical clients. Its focus on high-demand areas such as gene editing and iPSC biology positions it as a specialized partner in the rapidly growing cell therapy ecosystem, which is projected to expand significantly in the coming years. Despite its niche capabilities, Alstem operates in a competitive CRO landscape with larger players and in-house alternatives. The company’s private status and lack of disclosed funding or revenue data limit public visibility. However, its sustained operation since 2008 suggests a stable client base and recurring business. Future growth will likely depend on expanding service offerings, forming strategic partnerships, or capitalizing on increased demand for custom cell models in drug development. While no major near-term catalysts are publicly known, the company remains a competent player in its field. Conviction in its market position is moderate given the competitive dynamics and lack of recent news.

Upcoming Catalysts (preview)

• TBDExpansion of iPSC-Based Service Offerings70% success
• TBDStrategic Partnership with a Biotech or Pharma Firm40% success